Lyra Therapeutics (LYRA) Revenue & Revenue Breakdown
Lyra Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.56M
Latest Revenue (Q)
$598.00K
Lyra Therapeutics Revenue by Period
Lyra Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.56M | 14.31% |
| 2022-12-31 | $1.36M | 378.25% |
| 2021-12-31 | $285.00K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $1.24M | - |
Lyra Therapeutics generated $1.56M in revenue during NA 2023, up 14.31% compared to the previous quarter, and up 125.24% compared to the same period a year ago.
Lyra Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $598.00K | 12.41% |
| 2024-03-31 | $532.00K | 264.38% |
| 2023-12-31 | $146.00K | -73.16% |
| 2023-09-30 | $544.00K | 18.78% |
| 2023-06-30 | $458.00K | 11.71% |
| 2023-03-31 | $410.00K | 3627.27% |
| 2022-12-31 | $11.00K | -96.94% |
| 2022-09-30 | $359.00K | -11.79% |
| 2022-06-30 | $407.00K | -92.42% |
| 2022-03-31 | $5.37M | 1880.44% |
| 2021-12-31 | $271.00K | 1835.71% |
| 2021-09-30 | $14.00K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Lyra Therapeutics generated $598.00K in revenue during Q2 2024, up 12.41% compared to the previous quarter, and up 145.85% compared to the same period a year ago.
Lyra Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| AUTL | Autolus Therapeutics | $1.70M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| CGEM | Cullinan Oncology | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| NXTC | NextCure | - | - |
| TIL | Instil Bio | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
LYRA Revenue FAQ
What is Lyra Therapeutics’s yearly revenue?
Lyra Therapeutics's yearly revenue for 2023 was $1.56M, representing an increase of 14.31% compared to 2022. The company's yearly revenue for 2022 was $1.36M, representing an increase of 378.25% compared to 2021. LYRA's yearly revenue for 2021 was $285K, representing an increase of 100.00% compared to 2020.
What is Lyra Therapeutics’s quarterly revenue?
Lyra Therapeutics's quarterly revenue for Q2 2024 was $598K, a 12.41% increase from the previous quarter (Q1 2024), and a 30.57% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $532K, a 264.38% increase from the previous quarter (Q4 2023), and a 29.76% increase year-over-year (Q1 2023). LYRA's quarterly revenue for Q4 2023 was $146K, a -73.16% decrease from the previous quarter (Q3 2023), and a 1227.27% increase year-over-year (Q4 2022).
What is Lyra Therapeutics’s revenue growth rate?
Lyra Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 446.67%, and for the last 5 years (2019-2023) was 0%.